Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Sirolimus in Patients With Chemo-resistant, Recurrent or Metastatic Pancreatic Cancer

NCT03662412 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT03662412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03662412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Sirolimus in Patients With Chemo-resistant, Recurrent or Metastatic Pancreatic Cancer
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 1, 2018
Completion date
June 30, 2023
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer